The Series B financing The financing was co-led by ShangBay Capital and Features Capital, with additional participation from Engage Venture Partners, and JWC Ventures. Credit: Peshkova/Shutterstock

Laplace Interventional, a US based medical device company developing transcatheter tricuspid valve technology, has successfully closed a $12.9 million Series B financing round.

The financing, which was co-led by ShangBay Capital and Features Capital, with additional participation from Engage Venture Partners, and JWC Ventures, will be used to excel Laplace Interventional strategy for its First-in-Human (FIH) trials of its transcatheter valve system.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Laplace Intervention are developing a prosthetic valve which they claim can improve the treatment of Tricuspid Regurgitation (TR) and reduce the need for open-heart surgery.

Currently there are few treatment options for patients with TR and it is considered one of the most difficult heart valve issues to treat. There is a growing number of patients with TR which can be attributed to an aging population. According to a GlobalData report, in the US alone they expect the number of severe cases to go from 262,375 in 2023 to 371,041 in 2033. In the same period, the market value is expected to rise from $8.7 million to $901 million.

“Laplace has designed an ingenious medical technology and is positioned to solve one of the largest unmet clinical needs remaining in structural heart disease. Tricuspid valve patients and their physicians deserve an advanced world-class solution.” said William Dai, Founding Managing Partner at ShangBay Capital.

In 2021 Laplace Interventional raised $7.9 million in a Series A financing round which was led by a undisclosed investor, with participation from ShangBay Capital and Mayo Clinic.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Currently the transcatheter valve system is in the early stage of development and is yet to be cleared by the US Food & Drug Administration or any regulatory authority.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact